Recently stock market analysts have updated their consensus ratings on shares of Lpath, Inc. (LPTN).
Most recent broker ratings
01/20/2015 – Lpath, Inc. had its “buy” rating reiterated by analysts at MLV & Co. They now have a USD 11 price target on the stock.
10/15/2013 – JMP Securities began new coverage on Lpath, Inc. giving the company a “outperform” rating. They now have a USD 14 price target on the stock.
Lpath, Inc. has a 50 day moving average of 2.99 and a 200 day moving average of 2.61. The stock’s market capitalization is 6.96M, it has a 52-week low of 1.68 and a 52-week high of 5.88.
The share price of the company (LPTN) was up +8.52% during the last trading session, with a high of 3.00 and the volume of Lpath, Inc. shares traded was 26482.
Lpath, Inc. is a biotechnology company. The Company is focused on the discovery and development of lipidomic-based therapeutic antibodies. The Company’s product candidates include iSONEP, ASONEP and Lpathomab. The Company utilizes ImmuneY2 technology for the production of its antibodies. iSONEP is the ocular formulation of sonepcizumab, a monoclonal antibody (mAb) against sphingosine-1-phosphate (S1P). ASONEP is the systemic formulation of sonepcizuma, an mAb against the bioactive lipid S1P, a validated angiogenic factor and validated mediator of lymphocyte trafficking. ASONEP is indicated for various tumor types. Lpathomab is a humanized mAb against lysophosphatidic acid (LPA), a tumorigenic and metastatic agent and a validated contributor to neuropathic pain and traumatic brain injury. The product is indicated for the treatment of neuropathic pain, chemo-induced pain, traumatic brain injury and fibrosis. It has completed dosing in Phase Ia clinical trial in healthy volunteers.